Secondary hyperparathyroidism or hypocalcemia:
Indications for Calcitriol Injection:
Hypocalcemia in patients on chronic renal dialysis. Secondary hyperparathyroidism.
≥13yrs: Initially 1–2mcg (0.02mcg/kg) 3 times weekly (approx. every other day); usual range: 0.5–4mcg 3 times weekly. May increase by 0.5–1mcg at 2–4 week intervals. Adjust dose based on PTH levels: see full labeling.
<13yrs: not recommended.
Calcitriol Injection Contraindications:
Hypercalcemia. Vit. D toxicity.
Calcitriol Injection Warnings/Precautions:
Avoid concurrent Vit. D therapy. Maintain adequate calcium intake. Keep serum calcium times phosphate (Ca x P) product below 70. Monitor serum calcium and phosphorus twice weekly at start of therapy, and during dose adjustment. Monitor magnesium, alkaline phosphatase, parathyroid hormone levels (PTH) periodically; if PTH levels fall <1.5–3xULN, reduce calcitriol dose or discontinue. Pregnancy (Cat.C). Nursing mothers: not recommended.
Calcitriol Injection Classification:
Vit. D analog.
Calcitriol Injection Interactions:
Hypermagnesemia with magnesium-containing antacids. Arrhythmias with digitalis if hypercalcemia occurs.
Symptoms of hypervitaminosis D, hypercalcemia, hypercalciuria, hyperphosphatemia.
Formerly known under the brand name Calcijex.